Search Results
Nov 10, 2025, 21:24 ET Sdílení prosperity v inteligentní éře: Mezinárodní fórum inteligentní komunikace 2025 v čínském Wu-si
mezi nimiž byli Huang Wei, člen Čínské akademie věd (CAS); Dmitrij Palčunov, člen Ruské akademie inženýrství, mezinárodní spolupředseda Solvable Lab INT.; Guo Tong, předseda CCTV.com, předseda a generální ředitel Yangshipin.cn; Churchill Otieno, ředitel Afrického fóra editorů; Tong Jisheng, ředitel Čínské
More news about: CCTV.com
Nov 10, 2025, 21:18 ET Совместное процветание в интеллектуальную эпоху: В Уси состоялся Китайский международный форум интеллектуальных коммуникаций 2025 г.
Wei), академик Китайской академии наук (CAS); Дмитрий Пальчунов, академик Российской инженерной академии, международный сопредседатель, Solvable Lab INT.; Го Тун, председатель CCTV.com, председатель и генеральный менеджер Yangshipin.cn; Черчилль Отиено (Churchill Otieno), президент Африканского форума
More news about: CCTV.com
Nov 10, 2025, 21:14 ET Zdieľanie prosperity v inteligentnej ére: Čínske medzinárodné fórum inteligentnej komunikácie 2025 sa konalo vo Wuxi
okrem iných Huang Wei, akademik Čínskej akadémie vied (CAS); Dmitrij Palčunov, akademik Ruskej akadémie inžinierstva, medzinárodný spolupredseda Solvable Lab INT.; Guo Tong, predseda CCTV.com, predseda a generálny riaditeľ Yangshipin.cn; Churchill Otieno, prezident Afrického fóra redaktorov; Tong Jisheng, prezident
More news about: CCTV.com
Nov 10, 2025, 15:05 ET Wohlstand teilen im Zeitalter der Intelligenz: Das China International Intelligent Communication Forum 2025 wurde in Wuxi abgehalten.
Chinese Academy of Sciences (CAS); Dmitry Palchunov, Akademiemitglied der Russian Academy of Engineering, internationaler Co-Vorsitzender von Solvable Lab INT; Guo Tong, Vorsitzender von CCTV.com, Vorsitzender und Geschäftsführer von Yangshipin.cn; Churchill Otieno, Präsident des African Editors Forum; Tong
More news about: CCTV.com
Nov 10, 2025, 15:01 ET Partager la prospérité à l'ère intelligente : Forum international de la communication intelligente en Chine 2025 organisé à Wuxi
de l'Académie chinoise des sciences (CAS) ; Dmitry Palchunov, académicien de l'Académie russe d'ingénierie, coprésident international de Solvable Lab INT ; Guo Tong, président de CCTV.com, président et directeur général de Yangshipin.cn ; Churchill Otieno, président de l'African Editors Forum ; Tong Jisheng,
More news about: CCTV.com
Nov 10, 2025, 09:00 ET Rapid zalunfiban treatment at 1st point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications
Banerjee P. Continuous quality improvement for prehospital STEMI improved triage rates and achievement of gold standard < 90-min EMS-to-balloon time. Int J Emerg Med. 2025 Mar 12;18(1):53. doi: 10.1186/s12245-025-00863-x. PMID: 40075278; PMCID: PMC11905686.
More news about: CeleCor Therapeutics, Inc.
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227-1242.
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227-1242.
More news about: NOVO NORDISK INC.
Nov 09, 2025, 21:00 ET One Event. Multiple Ways to Grow Your Wealth.
https://www.togethernextlevel.co/invest360?utm_source=int&utm_medium=pr071125 About Next Level Academy
More news about: Next Level Academy
Nov 08, 2025, 10:54 ET Sharing Prosperity in the Intelligent Era: 2025 China International Intelligent Communication Forum Held in Wuxi
of the Chinese Academy of Sciences (CAS); Dmitry Palchunov, Academician of the Russian Academy of Engineering, International Co-chair, Solvable Lab INT.; Guo Tong, chairman of CCTV.com, chairman & general manager of Yangshipin.cn; Churchill Otieno, president of the African Editors Forum; Tong Jisheng,
More news about: CCTV.com
Nov 07, 2025, 22:39 ET Sharing Prosperity in the Intelligent Era: 2025 China International Intelligent Communication Forum Held in Wuxi
of the Chinese Academy of Sciences (CAS); Dmitry Palchunov, Academician of the Russian Academy of Engineering, International Co-chair, Solvable Lab INT.; Guo Tong, chairman of CCTV.com, chairman & general manager of Yangshipin.cn; Churchill Otieno, president of the African Editors Forum; Tong Jisheng,
More news about: CCTV.com
Nov 07, 2025, 07:46 ET Michter's lancia il suo bourbon invecchiato 20 anni
X. Contatto:Joseph J. Magliocco+1 (502) 774-2300 int. [email protected]
More news about: Michter's Distillery
Nov 06, 2025, 16:02 ET Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
$7.1 million. About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology
More news about: Intensity Therapeutics Inc.
Nov 05, 2025, 11:36 ET Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
References 1. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. 2. Servais A, et al. Kidney Int. 2012;82(4):454-464. 3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117. 4. Tarragón, B, et al. C3 Glomerulopathy Recurs Early
More news about: Swedish Orphan Biovitrum AB
Nov 05, 2025, 05:00 ET The Wait Is Over! ez1099 2025 Is Now Available for Effortless Tax Filing
Built for efficiency and accuracy, ez1099 offers: Easy setup and form preparation for 1099-MISC, 1099-NEC, 1099-INT, 1099-DIV, 1098, and more The ability to print recipient forms on plain white paper—no red
More news about: Halfpricesoft.com
Nov 04, 2025, 12:04 ET Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
1. Cameron JD, et al. Annu Rev Nutr. 2017;37:183-205. 2. Dalton M, et al. Int J Obes (Lond). 2017;41(8):1232-6.3. Alfouzan NW, et al. Physiol Behav.
More news about: Currax Pharmaceuticals LLC
Nov 04, 2025, 06:30 ET Elastomeric Infusion Pumps Market worth $1.49 billion by 2030 - Exclusive Report by MarketsandMarkets™
companies, including Baxter (US), B. Braun SE (Germany), NIPRO (Japan), AVNS (US), Vygon (France), and WOOYOUNG MEDICAL CO., LTD. (South Korea), Shanghai INT Medical Instruments Co., Ltd. (China), Ambu A/S (Denmark), Palex (Spain), and DAIKEN MEDICAL CO., LTD. (Japan).
More news about: MarketsandMarkets
Oct 31, 2025, 09:00 ET AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
Rao SV, O'Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862. Vinci P, Di Girolamo FG, Panizon E, et al. Int J Environ Res Public Health. 2023;20(18):6721. Published 2023 Sep 6. doi:10.3390/ijerph2018672. Stein EA, Wasserman SM, Dias
More news about: Amgen
Oct 31, 2025, 08:30 ET CW Bancorp Reports Third Quarter 2025 Financial Results
Int Bearing Due from Banks & FFS
More news about: CW Bancorp
Oct 31, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the
More news about: Intensity Therapeutics Inc.
Oct 30, 2025, 07:30 ET Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
to the start of the event. About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporos Int. 2024 Nov;35(11):1919-1930. doi: 10.1007/s00198-024-07161-x. Epub 2024 Jul 23. PMID: 39042292; PMCID: PMC11499533. Available at:
More news about: Celltrion
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Zamtocabtagene autoleucel, Cemacabtagene ansegedleucel, LMY-920, PRGN-3006 UltraCAR-T, LMY-920, P-BCMA-ALLO1, AUTO4, Descartes-8, Rapcabtagene autoleucel, INT2104, UB-VV111, and others. Discover which indication is expected to grab the major CAR T-cell therapy
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 07:30 ET Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System
A V. Three-Year Results with a Ringless Third- Generation Porous Plasma Sprayed Acetabular Component in Primary Total Hip Arthroplasty. Surg Technol Int [Internet]. 2017 Jan; 30:295—299. Available from:
More news about: Zimmer Biomet Holdings, Inc.
Oct 27, 2025, 16:10 ET LINKBANCORP, Inc. Announces Strong Third Quarter 2025 Earnings and Declares Dividend
Int. Earn. Cash
More news about: LINKBANCORP, Inc.